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Abstract
Since the early 2000s, aid organizations and developing country governments have invested heavily in AIDS treatment. By
2010, more than five million people began receiving antiretroviral therapy (ART) – yet each year, 2.7 million people are
becoming newly infected and another two million are dying without ever having received treatment. As the need for
treatment grows without commensurate increase in the amount of available resources, it is critical to assess the health and
economic gains being realized from increasingly large investments in ART. This study estimates total program costs and
compares them with selected economic benefits of ART, for the current cohort of patients whose treatment is cofinanced
by the Global Fund to Fight AIDS, Tuberculosis and Malaria. At end 2011, 3.5 million patients in low and middle income
countries will be receiving ART through treatment programs cofinanced by the Global Fund. Using 2009 ART prices and
program costs, we estimate that the discounted resource needs required for maintaining this cohort are $14.2 billion for the
period 2011–2020. This investment is expected to save 18.5 million life-years and return $12 to $34 billion through increased
labor productivity, averted orphan care, and deferred medical treatment for opportunistic infections and end-of-life care.
Under alternative assumptions regarding the labor productivity effects of HIV infection, AIDS disease, and ART, the
monetary benefits range from 81 percent to 287 percent of program costs over the same period. These results suggest that,
in addition to the large health gains generated, the economic benefits of treatment will substantially offset, and likely
exceed, program costs within 10 years of investment.
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Introduction
Flows of bilateral and multilateral aid over the past decade,
combined with the domestic financial contributions of many
countries, have fueled a remarkable scale-up in AIDS treatment
and prevention programs in low and middle income countries.
Starting with just a few thousand patients in 2002, UNAIDS and
WHO report that by the end of 2009 more than five million people
were enrolled in antiretroviral therapy (ART) programs in these
countries [1]. Despite these impressive gains, only a third of the
estimated 15 million HIV-infected persons with the most acute need
(according to the WHO’s 2010 eligibility definition) have access to
treatment [1,2]. Each year two million people still die from AIDS
(most without having ever received ART) and approximately 2.7
million persons are newly infected by HIV [3,4].
Several studies have suggested that the intrinsic value of the
health gains generated from ART is worth the cost of treatment,
thereby arguing for greater investment in ART programs to meet
growing treatment needs [5,6]. However, the 2008–2010 global
recession, flattening aid budgets, and fiscal tightening in many
AIDS-affected countries are threatening the ability of donors and
countries to continue scaling up ART. In this context, policy
makers deciding whether to commit additional resources to ART
programs will want to consider not only the cost and health
impacts of program continuation, but also the likely economic
benefits of doing so.
To estimate the societal-level economic impact of ART, we
analyzed three streams of benefits from AIDS treatment accruing
over time to a cohort of patients enrolled on treatment in
programs supported by the Global Fund: (1) restored labor
productivity amongst workers with AIDS, (2) orphan care
expenditures avoided because parents remain alive on ART, and
(3) delayed end-of-life care costs associated with death from AIDS.
These streams of economic benefits were selected because they
offset the cost of treatment over short time horizons and therefore
may be especially salient to policy-makers concerned with health
budgets, household economic stability and societal-level economic
growth. Our model is applied to patients in AIDS programs across
low and middle income countries where the Global Fund to Fight
AIDS, Tuberculosis and Malaria (Global Fund) cofinances ART,
alongside domestic and other external funding. Results should be
seen as broadly applicable to national ART programs financed by
other international organizations and from domestic public and
private sources.
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Materials and Methods
Overview
The full cohort of 3.5 million ART patients who participate in
treatment programs co-financed by the Global Fund are found
across 98 countries (Table S1), 80 percent of these in just 20
African countries. The health impact and gross program cost of
maintaining this cohort of patients over the next decade were
estimated using methods and data detailed in a companion paper
[7]. We extend the model, in order to estimate economic returns
from this investment. Our approach to estimating the economic
returns of the ART program is to compare it to a ‘null scenario’ in
which such a treatment effort does not exist [8,9]. We thus
calculated the ratio of the full program costs (of which a portion is
financed by Global Fund) to the set of economic benefits generated
through the program. In doing so, we estimated the return on
investment of the ART program effort. A summary of model
parameters is shown in Table 1.
Health impact of ART
We first modeled the survival through 2020 of the 3.5 million
patients who will be on ART as of 2011 in Global Fund-supported
country programs, based on service delivery targets [10,11,12] of
ongoing Global Fund grants and proposals through the 10th round
of applications in December 2010 [13]. To calculate the survival
gain attributable to ART, we compared survival on ART to that of
untreated patients whose disease has progressed to the point of
ART eligibility (e.g. CD4,200 cells/mm3), using established
epidemiological methods [14,15]. We assumed the probability that
ART patients survive to be 79.5 percent in their first year and 96
percent for subsequent years [3]. The difference represents the
survival benefit (life-years gained) attributable to ART, as
illustrated in Figure 1.
Costs of ART programs
Program-level recurrent costs (of which the Global Fund
finances a portion alongside domestic and other donor resources)
were estimated by summing the cost of antiretroviral drugs
(ARVs), lab‘oratory testing and service delivery (personnel,
supplies, facilities, etc.). All patients in the cohort have already
initiated ART care, so counseling and testing and costs associated
with treatment initiation were not included. Country-reported
ARV utilization patterns and procurement prices [16,17] were
analyzed to estimate country-specific costs for first-line and
second-line ARV regimens. Across the countries in our study,
the median annual cost per patient was $204 and $1,238,
respectively (see [7]). The median annual cost of monitoring
patients with laboratory tests ($180) obtained from a synthesis of
15 published reports from low and middle income countries was
applied to the entire cohort [7]). Estimates of service delivery costs
were based on eight studies of inpatient and outpatient care for
ART patients [7]. The median rates of utilization obtained from
these studies were applied to all patients in our analysis. Unit costs
per day of hospitalization and per outpatient clinic visit were
Table 1. Key model parameters.
Parameter Base Case (source) Sensitivity analysis
Patients alive on ART in 2011 Patient targets of Global Fund-supported ART programs for
end 2011 (country-level) [7,18]
N/A
Survival with and without ART 79.5% survival at 12 months, and 96% for each subsequent
year, for all countries [3,7]
N/A
Value of full-time employment of asymptomatic HIV-infected
adults
Gross national income per working age person (GNIpwap)
[39,45]
50% GNIpwap
Labor productivity of untreated symptomatic HIV/AIDS cases
relative to asymptomatic HIV-infected adult
20% (see Information S1) 0%, 40%
Labor productivity of patients established on ART relative to
asymptomatic HIV-infected adult
75% (see Information S1) 60%, 90%
Fraction of HIV patients that are working age 90% [4]
Months after starting ART before productivity rebounds 6 (see Information S1) N/A
Months of reduced productivity associated with treatment
failure under ART
12 months before death N/A
Orphan-years averted per patient-year of ART Country-specific, varying from 0.32 to 0.76 (average 0.5),
computed with Spectrum [14] among the 14 countries with
largest numbers of Global Fund-supported ART and services for
orphans and vulnerable children. Other countries extrapolated
adjusting for total fertility rate. Orphans are defined as children
under 18 years losing one or both parents
N/A
Fraction of orphans needing care and support Equal to fraction of full population below nationally defined
poverty line, which ranged between 25% and 75% (average
across Global Fund-supported ART patients: 46%) in the 14
countries with largest numbers of Global Fund-supported ART
and support for orphans and vulnerable children [18]
N/A
Cost of care for orphans and vulnerable children per
orphan-year
$224, based on data from 300 NGOs operating in 7400 sites in
sub-Saharan Africa, adjusted for expected economies of scale
during program scale-up [55]
N/A
End-of-life care of AIDS patients: lifetime cost $480 in patients without ART [7,57], $160 in patients with ART,
based on an assumed three-fold shorter terminal illness compared
to patients not accessing ART
doi:10.1371/journal.pone.0025310.t001
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country-specific, based on WHO-CHOICE estimates [18,19] and
resulted in median service delivery costs of $138 per patient-year
[7]. Proportions of patients on each regimen were projected using
trends in migration from first- to second-line regimens estimated
from treatment data reported by national AIDS programs to the
WHO in 2009 [20]. In conducting sensitivity analysis, we
considered possible changes in ARV cost and service delivery
over the coming decade.
Benefits: restored labor productivity
AIDS has a substantial negative effect on patients’ productivity,
since many of those who become infected are of prime working
age [21,22,23]. As HIV progresses, patients develop opportunistic
infections and other symptoms that limit their ability to work. By
the time HIV-infected workers are diagnosed and become eligible
for ART, they have often missed days of work due to AIDS-related
illness, which worsens if left untreated, leading to increased sick
leave or departure from the labor force, and death typically within
two years of being diagnosed with AIDS [24,25,26,27].
In contrast, ART rapidly restores physical function and extends
life expectancy [28,29,30,31,32,33], thereby maintaining worker
productivity and keeping families intact [10,34,35,36]. Longitudi-
nal studies among agricultural workers in Kenya [10,11,12,30,37]
and miners in Botswana [35] and Uganda [38] demonstrate a
consistent V-shaped pattern for labor force participation and
productivity over the course of HIV infection, declining sharply as
symptoms worsen in the months before ART initiation and
rebounding to near-normal within a few months (Table S2).
Studies from India [39], Cambodia [32], Chile [40], Ivory Coast
[41], and South Africa [42,43,44,45] also indicate that ART can
restore labor productivity. While no studies have followed patients
for the length of time modeled in our benefits analysis (10 years),
longitudinal studies have not observed any fall off in productivity
restored by ART in the first three years after treatment initiation
[11].
These findings are tempered by other evidence. For those who
lose their jobs upon falling sick with AIDS prior to initiating
treatment, lack of employment opportunities in the local labor
market can limit the productivity gains due to ART [44]. In
addition, some studies that measured output found that patients
may not return fully to productivity levels they experienced prior
to becoming symptomatic [37].
UNAIDS estimates that worldwide, only seven percent of HIV
cases are in persons aged less than 15 years [4]. We therefore
assumed that 90 percent of the HIV cases in our cohort were of
working age, in order to account for pediatric cases as well as the
Figure 1. Projected health impact of ARV treatment in Global Fund countries. Survival of newly enrolled and surviving HIV/AIDS patients
on ART in Global Fund-supported programs, according to end-2009 grant results and 2010–11 targets of ongoing grants and approved proposals
through the 10th round of applications, assuming no additional patient enrolments after 2011. Life years gained is calculated as difference between
the ART scenario and a no-ART counterfactual. See [7] for more details.
doi:10.1371/journal.pone.0025310.g001
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small fraction of HIV cases that may be occurring in persons who
have retired from the labor market due to advancing age. Labor
productivity of patients on ART was calculated according to
country-specific labor market characteristics, including the fraction
of the population that is of working age and the average per capita
income [46,47].
Recent longitudinal studies in southern African countries
suggest that middle income groups or the relatively wealthier
within a country are at a somewhat higher risk of being infected
[48,49,50] and more likely to access ART when in need of
treatment [49,51]. Uncertainty in generalizing these findings to all
countries in our data set, led us to assume that, in our base case,
gross national income (GNI) per working age person is a valid
proxy for the productivity of working age HIV-infected persons in
the asymptomatic early stage of disease course (i.e. those not in
need of treatment). However, using GNI per working age person
may overestimate the market value of labor if HIV risk is positively
correlated with poverty [52] or if economic output is dominated by
natural resource extraction activities that employ a relatively small
portion of the labor force [51]. Therefore, we subjected this
assumption to sensitivity analysis.
Based on literature review summarized above (and in
Information S1), we assumed that the productivity of symptomatic
adult HIV-infected persons in need of, but not accessing, ART is
reduced to 20 percent of their pre-symptom level. We further
assumed that after six months on ART, a patient’s productivity is
partially restored to 75 percent of pre-symptom level. As shown in
Table 1, this level is maintained until one year before death – the
period with clinical AIDS that follows ART failure, when
productivity again drops to 20 percent pre-symptom level.
Given the uncertainties surrounding these best available
estimates of productivity, we conducted sensitivity analyses using
a range of values for the assumed productivity of HIV patients
with and without ART that were both higher and lower than base
case assumptions. The sensitivity analyses separately address: (a)
the possibility that HIV-infected persons would, in the absence of
HIV infection, tend to engage in less productive work than
country average; (b) the extent to which ART restores an HIV-
infected person’s productivity to the level achieved prior to onset
of symptomatic disease; and (c) the extent to which clinical AIDS
and pre-AIDS HIV-associated illness resulting from a lack of ART
or a failure to respond to ART reduce an infected person’s
productivity. We separately considered a scenario in which ART
patients leaving the workforce due to AIDS are easily replaced
from a stock of unemployed workers, and productivity losses due
to AIDS are limited to the transition costs (i.e. recruitment and
training) of replacing workers (see Information S1).
Benefits: orphan care costs averted
AIDS deaths have orphaned an estimated 16.6 million children
by 2009, of whom 90 percent are in sub-Saharan Africa [1].
Orphans (children with one or more deceased parent) are at
higher risk for negative health and educational outcomes [53],
generating an urgent need for orphan support including food,
clothing, school fees, healthcare, and income generating activities
[54,55]. This support is typically delivered through community
programs and/or within households of HIV-infected individuals
who foster AIDS orphans [56].
We computed orphan-years averted by per adult life-year
gained due to ART using the Spectrum AIDS Impact Model [14]
for each of 14 countries, including the 10 with the most Global
Fund-supported ART patients and the 10 with the most Global
Fund-supported services for orphans and other vulnerable
children [18]. Across these 14 countries, between 0.32 and 0.76
orphan-years (average 0.5) are averted each year that an adult
patient survives on ART. The number varies across countries
because of differences in fertility rates, child mortality and the age
distribution of HIV-positive adults. For other Global Fund-
supported countries, an estimated number of orphan-years averted
per life-year gained on ART was derived from the 14 modeled
countries, interpolating linearly based on country-specific fertility
rates. For more on the methodology, please see Table 1 and Figure
S1.
The averted cost of orphan care was assumed to be $224 per
orphan-year, based on a review of service cost data from 300 non-
governmental organizations, covering 7400 sites in 22 countries in
sub-Saharan Africa [55].
Benefits: end of life care delayed
We assumed that AIDS patients not accessing ART received
end of life care over the last 1.5 years before death from AIDS.
The cost of this care averaged $480 per patient not accessing
ART, based on $49 worth of non-ARV drugs and the country-
specific cost of 9.7 inpatient days and 5.5 outpatient days of clinical
care [13,19,57]. For patients dying after failure of ART, the
additional end-of-life care cost was estimated at one-third of the
cost per patient not accessing ART (cross-country average $160),
incurred over the last six months of life [7].
All costs and benefits were discounted at three percent per
annum as recommended by the WHO [58] and the US Public
Health Service [59], and expressed in 2008 US dollars.
Undiscounted results are also reported.
Results
ART program costs
With (without) discounting, program costs total $14.2 billion
($16.6 billion) [7].
Benefits of ART
Over the 10-year period, ART for the 3.5 million patient initial
cohort saves a cumulative 18.5 million life-years [7]. With base
case assumptions regarding productivity, the corresponding gross
discounted economic benefits amount to $34.0 billion (Table 2).
Figure 2 illustrates the trends in program costs, productivity gains,
and costs averted on orphan and end-of-life care resulting from
ART over the 10 years.
Productivity gains follow the trend in patients surviving on
ART, reaching a maximum in 2012, about a year after the peak in
total number of patients on ART in 2011. Across the Global Fund-
supported patient cohort, the value of increased labor productivity
reaches $3.8 billion per year in 2012, and gradually declines to
$2.5 billion per year by 2020 (Figure 2). Over the 10-year study
period, the total discounted productivity gain is $32 billion.
The value of averted orphan care increases over time, in direct
proportion to the number of life-years added each year for patients
receiving ART, as can be seen in Figure 2. The discounted
cumulative benefit over the decade is $0.83 billion. The monetary
value of delaying end-of-life care is $1.4 billion over the study
period, with annual savings peaking in 2012.
Net benefits of ART
In our base case, the estimated net benefit – the difference
between estimated economic benefits and ART program cost – is
positive, amounting to $19.8 billion, while the gross benefit ($34.2
billion) equals 240 percent of the program cost over the study
period. The benefit-cost ratio was not sensitive to discounting
(Table 2).
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Sensitivity Analysis
In Table 3 and 4, we show the results from three-way sensitivity
analysis that considers the uncertainty about the magnitude of
effect of HIV and ART on productivity. Estimated benefits ranged
from 81 percent to 287 percent of the ART program cost. Under
most combinations of assumptions about the ability of ART to
restore productivity and about the baseline productivity of
asymptomatic HIV patients (i.e. the maximal level of productivity
that could be restored), the projected costs of ART are fully
recouped. Even in the most pessimistic scenario, where the
baseline value of productive output of an asymptomatic ART
patients is just half of GNI per working age person, and ART only
increases an AIDS patient’s productivity from 40 percent to 60
percent of baseline productivity, the benefit streams totaled $11.5
billion and offset 81 percent of the cost of ART programs (Table 4).
Tables S3 and S4 shows sensitivity analyses of ARV costs trends
and coverage of viral load monitoring, respectively. If first-line
regimen prices decline five percent per year through 2020, and
second-line prices fall by 15 percent per year through 2015,
program cost reductions amounted to $2.1 billion (15 percent),
Figure 2. Comparing ART program costs and benefits. Annual discounted ART program costs, productivity gains, orphan care costs averted,
and net monetary benefits for the cohort of Global Fund-supported patients on treatment as of 2011.
doi:10.1371/journal.pone.0025310.g002
Table 2. Program costs and economic benefits for the cohort of 3.5 million people on ART in 2011, cumulative 2011–2020 (US$
billions).
Line Item Base case, discounted Base case, undiscounted
Program cost $14.2M $16.6M
Labor productivity $31.8M $37.1M
Orphan care costs averted $0.83M $1.0M
End-of-life OI treatment costs averted $1.4M $1.5M
Total benefit $34.0M $39.6M
Net benefit $19.8M $23.0M
Benefit/cost 240% 239%
doi:10.1371/journal.pone.0025310.t002
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raising the baseline benefit-cost estimates for ART from 240
percent to 281 percent. The companion paper also explores other
possible shifts in program cost, including higher first-line drug
costs as a result of the phasing out of stavudine, which would
increase program costs by seven percent, and accelerated
migration to second-line as a result of increased use of viral load
monitoring, raises discounted program costs by $3.5 billion (25
percent). In this case, the benefit-cost estimate falls modestly from
240 percent in the base case to 192 percent.
If patient retention in ART programs were lower than in the
base case, both program costs and benefits are reduced and the
benefit-cost ratio declines modestly from 240 percent to 226
percent (Table S5). If productivity losses were limited only to the
‘friction costs’ of replacing lost workers from a stock of
unemployed persons, the total economic benefits of ART would
not fully offset program costs. Still, nearly three-quarters of the
program costs would be recouped at the societal level (Table S6).
Discussion
Our analysis focuses on the valuation of economic benefits and
related costs that accrue from maintaining current patients in
ART programs being cofinanced by the Global Fund and a range
of other complementary domestic and external sources. Though
considerable uncertainty remains, and impact at the level of
individual countries may vary substantially, we find that the
monetary value of productivity gains, orphan care and end-of-life
AIDS care costs averted or delayed are likely to exceed ART
program costs.
We estimated the economic returns of the ART programs by
comparing them to a ‘null scenario’ in which such a treatment
effort does not exist [8,9]. Our results, therefore, correspond to the
overall value of ART programs. We did not attempt to directly
compute the marginal return to Global Fund’s investment in
ART, imagining what would have happened without the Fund’s
financial participation in ART. Nor do we predict what would
happen in the coming years if the Global Fund withdrew its
support for ART programs – a policy very unlikely to occur.
Recent analysis suggests, however, that if donors stopped funding
ART programs, only a portion of these resources, perhaps around
40 percent, would be replaced by domestic sources [60].
Our findings provide evidence that large scale ART in low and
middle income countries yields a stream of economic benefits that
is likely to offset substantially or exceed the costs of delivering
AIDS treatment to millions of patients in these countries. With the
Global Fund currently supporting on average about a quarter of
the program-level costs of ART across the 98 country programs
[13], and other donors contributing significant additional portions,
these external funders can justifiably argue that their investments
are yielding large economic benefits to recipient countries, in
addition to the health gains accruing to the millions of patients on
AIDS treatment. Similarly, as national governments gradually
assume a larger share of the costs of ART programs, they should
also see domestic spending on ART as generating large economic
benefits that will likely outweigh the costs incurred.
Costs and benefits accrue to a range of stakeholders. Our
analysis included the full cost of ART paid for by a combination of
donor funds, domestic government revenue, and direct payments
of patients or (in rare cases) private insurers. Increased economic
productivity directly benefits patient households. The national
government also experiences a follow-on benefit from patients
returning to work, in the form of increased taxes collected on
incomes and other economic activity (e.g. sales taxes), which our
analysis did not incorporate. The presented cost savings on orphan
care and end-of-life AIDS care are shared between households of
patients and their relations and national governments.
In our model, productivity gains from ART increase propor-
tionally with per capita GNI. Although treatment costs are also
correlated with GNI, per-patient net benefits are lower for
countries with weaker economies or where HIV is concentrated
in socioeconomically marginalized subpopulations. While our
analysis makes adjustments wherever possible for country-level
variation, for many parameters in our model only regional
estimates were available. Therefore, we report only aggregate
results.
Our findings demonstrate the value of maintaining the current
cohort of patients on ART, as we do not estimate economic
returns to a further scale up of ART services. Such actions are
likely to have favorable benefit-cost profiles, but their exact value
will depend on many additional factors that our analysis did not
have the capacity to consider. For example, evidence suggests that
more productive members of society are more likely to access
ART when coverage is low, because of their relatively greater
resources, knowledge, and proximity to services [51]. As national
ART programs expand, the incremental patients may be relatively
less economically productive, and reaching them may be more
difficult and expensive. On the other hand, economies of scale in
treatment service delivery may offset these other factors that would
tend to drive up unit costs and lower benefits.
Our estimates of ART program cost, particularly for service
delivery and for orphan care, are limited by shortcomings in the
Table 3. Discounted monetary benefits, net benefit (benefits minus program costs), and benefit as a percentage of ART program
costs, from restored labor productivity, averted orphan care and delayed end-of-life care combined, cumulative over 2011–2020
(US$ billions) Bold text indicates the base case scenario estimate.
Productivity of untreated patient in need of ART (as percentage
of asymptomatic HIV patient productivity)
Productivity of patient responding to treatment (as percentage of asymptomatic HIV
patient productivity)
90% 75% 60%
20% Benefit $40.7 $34.0 $27.3
20% Net Benefit $26.5 $19.8 $13.1
20% Benefit/cost 287% 240% 192%
40% Benefit $38.9 $32.2 $25.5
40% Net Benefit $24.8 $18.0 $11.3
40% Benefit/cost 275% 227% 180%
doi:10.1371/journal.pone.0025310.t003
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available data. In some cases, it was necessary to adapt findings
from studies in a subset of countries to our whole sample. While
we used reasonable methods for doing so, only the collection of
country-specific data will enable us to refine this analysis of ART’s
economic impact to the point where precise estimates for
individual countries can be generated. Recently established
routine tracking of national program expenditures will in the
future generate useful data on country variations and time trends
in per-patient and program-level costs of ART and other services
[61], including effects of ARV drug price declines, changing
WHO treatment regimen recommendations [28], and the
proportion of patients on first- and second-line ARV regimens.
Improved estimation of productivity gains realized in different
settings will further benefit from ongoing efforts to enhance
monitoring of patient adherence, retention and quality-of-life
(including employment) outcomes, especially over the longer term
as patients accumulate years on ART.
Future disaggregation of patient retention and productivity
effects by gender could also sharpen these estimates of economic
returns. As ART coverage is slightly higher in women than in men
but labor force participation and wages tend to be lower, gender
disaggregation could be expected to lower the estimated benefits
somewhat. However, the impact of ART on non-monetized
activities disproportionately performed by women in the house-
hold and informal sector – which are not captured in our analysis
– is likely to be substantial.
Our assessment of the benefits of ART presented here should be
taken as a first approximation of the magnitude of the economic
returns to investments in AIDS treatment. While productivity
gains, orphan benefits, and cost offsets within clinical HIV care are
the most tangible returns on investment that policy-makers may
consider when evaluating the affordability of ART programs in the
future, these benefit streams capture only a fraction of wider
economic, social and health benefits from AIDS therapy.
Accounting for second-order negative economic effects of AIDS
that may be mitigated by ART, such as a slowing of economic
growth due to reduced savings and investment, erosion of human
capital, and lower expected lifetime earnings of children who must
miss school to care for, or replace the earnings of, a sick parent,
would increase the economic benefits we have estimated here.
Economists have attempted to capture these second-order
effects and measure the impact of AIDS on economic growth
using macroeconomic approaches that simulate the entire
economy of a country in computable general equilibrium models.
These studies suggest that, in the absence of effective treatment,
substantial productivity losses – on the order of a one percent
reduction in gross domestic product (GDP) growth per year –
could occur in countries with generalized HIV epidemics
[6,49,62,63,64,65,66].
Our analysis, like these macroeconomic modeling approaches,
does not attempt to measure the full social welfare impact of ART.
Such an exercise would likely show that benefits derived from
ART are greater than the productivity gains and cost offsets in
orphan and end-of-life care [67]. The WHO’s benchmarks for
cost-effectiveness of averting disability-adjusted life years imply
that an incremental life year gained has a monetary value
equivalent to a multiple (one to three times) of GDP per capita
[68]. Likewise, studies of the ‘value of statistical life’, generally find
that people value life years gained at an amount that is greater
than their expected income in those years of life, although private
willingness-to-pay for mortality risk reductions varies with country,
income and age [69,70].
Despite the restriction of our analysis to a set of first-order
economic benefits, the findings presented in this paper underscore
the value to low and middle income countries and their external
partners of continuing funding for AIDS treatment programs,
beyond the moral and social arguments that many have advanced.
Progress in delivering high-quality treatment services more
efficiently over the next few years, thereby lowering the average
cost per patient-year of ART, will help to further raise the benefit-
cost balance and thus the economic rationale for investing in this
area.
Supporting Information
Figure S1 Correlation between Total Fertility Rate and
years of ART required to avert one orphan-year. The
number of patient-years of ART required to avert one year of
orphanhood was modeled for 14 key countries with ART
programs supported by the Global Fund, using the Spectrum
model [1]. Together, these countries are responsible for 69 percent
of Global Fund ART patients and 94 percent of Global Fund-
supported OVC services: Ethiopia, Malawi, Tanzania, Rwanda,
Cambodia, India, Burundi, Kenya, Lesotho, Nigeria, South
Africa, Uganda, and Zambia. To estimate years of ART required
to avert one orphan-year for all other Global Fund-supported
countries, we extrapolated the findings from the 14 modeled
countries by linear interpolation based on country-specific fertility
rate.
(TIF)
Table 4. Discounted monetary benefits, net benefit (benefits minus program costs), and benefit as a percentage of ART program
costs, from restored labor productivity, averted orphan care and end-of-life care combined, cumulative 2011–2020 (US$ billions),
with average productivity of asymptomatic HIV infected persons valued at 50% of GNI per person of working age.
Productivity of untreated patient in need of ART (as
percentage of asymptomatic HIV patient productivity)
Productivity of patient responding to treatment (as percentage of asymptomatic HIV patient
productivity)
90% 75% 60%
20% Benefit $20.3 $16.9 $13.6
20% Net Benefit $6.1 $2.7 2$0.6
20% Benefit/cost 143% 119% 96%
40% Benefit $18.2 $14.9 $11.5
40% Net Benefit $4.1 $0.7 2$2.6
40% Benefit/cost 129% 105% 81%
doi:10.1371/journal.pone.0025310.t004
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Table S1 Countries with Global Fund supported ART
programs.
(DOCX)
Table S2 Longitudinal studies of labor force participa-
tion and productivity of adult HIV/AIDS patients, with
and without ART.
(DOCX)
Table S3 Sensitivity analysis of program cost assump-
tions.
(DOCX)
Table S4 Sensitivity of program cost estimates to
trends in ARV price and coverage of viral load monitor-
ing.
(DOCX)
Table S5 Sensitivity analysis of patient retention on
ART.
(DOCX)
Table S6 Program costs and economic benefits for the
cohort of 3.5 million people on ART in 2011, Results of
sensitivity analyses, cumulative 2011–2020 (US$ bil-
lions).
(DOCX)
Information S1 An elaboration on Materials and Meth-
ods.
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